Category Archives: Int’l Practice and Policy

IP Update – Canada | New Patent Rules released: 12 Notable Changes & Tips

Guest Post from David Schwartz and Jeff Leuschner of  Smart & Biggar. On December 1, 2018, the Canadian government released its proposed new Patent Rules in the Canada Gazette, Part I. This is one of the last steps necessary for implementing significant changes … Continue reading

Posted in Int'l Practice and Policy | Tagged , , , | Leave a comment

Do You Really Want to File for Pharma Patent Protection in Canada, India or Ecuador?

IPO Letter Reports Weaknesses in IP Protection Around the World In a 27 page letter dated February 8, 2018 and sent to Sue Chang at the Office of the U.S. Trade Representative, the Executive Director of IPO, Mark Lauroesch, extensively … Continue reading

Posted in Govt Policy/PTO Policy, Int'l Practice and Policy, Non-U.S. Practice | Tagged , , | 1 Comment

Canada’s ‘’Sister” Prior Art Law Differs From Ours, Eh!

I recently received a well-written post from Smart & Biggar/Feherstonhaugh in Toronto reminding me that a publication by the inventor only shields a later third-party publication from being a bar if the second publication was derived from the inventor and a … Continue reading

Posted in Int'l Practice and Policy | Tagged , , , , , , , | Leave a comment

Review of Indian Working Requirements

This newsletter (attached below) from a leading Indian firm, contains a good review of the perils of the working requirement in India. It also provides a good summary of three recent decisions holding pharma patents invalid for obviousness. What is striking is … Continue reading

Posted in Int'l Practice and Policy | Tagged , , , , , , , , | Leave a comment